Mesoblast Limited (NASDAQ:MESO) shares are trading higher on Wednesday.
The company announced that the FDA accepted its biologics license application for RYONCIL and has agreed to a priority review.
Related Link: Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Status
Mesoblast is an Australian based regenerative medicine company and provides treatments for inflammatory ailments, cardiovascular disease and back pain.
Mesoblast shares traded higher by 6.39% to $4.66 at time of publication. The stock has a 52-week range between $10.88 and $3.12.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
